Thursday, Oct 29, 2020 9:00a -
Friday, Oct 30, 2020 5:45p
Boston, Massachusetts 00000
$1299.00 - 2199.00
Lectures & Conferences
• Implement robust, patient-centric supply chains for clinical to commercial readiness
• Optimize patient care with best practice guidelines and integrated platforms
• Maintain product quality at scale for seamless delivery of autologous and allogeneic therapies
As an increasing number of candidates enter the clinic and promise to be a mainstay in the future of cancer treatment, cell therapies pose unique supply chain challenges.
At the inaugural Patient-to-Patient Supply for Cell Immunotherapies Summit, this community will share their expertise and propose best practice for seamless vein-to-vein delivery at the clinical and commercial scale.
From time and temperature sensitivity, to patient-facing service and integrated platforms, a seamless vein-to-vein supply chain is central in maintaining cell immunotherapy safety and efficacy at scale and maximizing the patient experience.
Join the strategic experts from GSK, bluebird bio, Adaptimmune, Celgene, BMS and more, to discuss best practice for patient-facing supply chains and build integrated platforms for chain of identity and end-user access.
Early booking and academic discounts available - see the website for more details.
+1 617 455 4188
Conference Only (Industry Digital Pricing): USD 1699.00,
Conference Only (Academic Digital Pricing): USD 1299.00,
Conference Only (Standard Digital Pricing): USD 2199.00
Speakers: Albert Ribickas, Supervisor, Cell Therapy Facility, Moffitt Cancer Center, Alexandra Gomez, Associate Director Patient Services Operations, bluebird bio, Amol Thote, Senior Director Cell and Gene Therapy Network Strategy and Supply Chain Management, Bayer, Anthony Colenburg, Director of Quality, Adicet Bio, Inc, Ben Wang, Executive Director of the Georgia Tech Manufacturing Institute, Georgia Institute of Technology, Bob Amareld, Head of Supply Chain, Precision Biosciences, Chelsea White, Schneider National Chair in Transportation and Logistics, Georgia Institute of Technology, Christopher Baldwin, Supply Chain Director, Cell and Gene Therapy, GSK, David Boodey, Supply Chain Manager, Adaptimmune Therapeutics, Debra Susarchick, Chief Product Officer, TrakCel, Devin Blass, Senior Director of Manufacturing and Supply Chain, Talaris Therapeutics, Emilie Gauthy, Industrialization Manager, Celyad, George O’Sullivan, Head of Supply Chain, Elevate Bio, Gregory Russotti, Chief Technology Officer, Century Therapeutics LLC., Jean Stanton, Director Commercial Apheresis Operations, The Janssen Pharmaceutical Companies of Johnson and Johnson, Kawa Chiu, Vice President of CMC Supply Chain, Lyell Immunopharma, Kirstin Powel, Global Head, External Quality Operations, Novartis Cell and Gene Therapy, Nan Zhang, GMP Cellular Therapy Lead, Children’s National Health System, Neeraj Shah, Global Clinical Supply Chain Excellence, Bristol-Myers Squibb, Reggie Foster, Sr. Director of Labelling, Logistics, and Packaging, Kite: A Gilead Company, Richard McFarland, President, Standards Coordinating Body, Shah Ahmad, Associate Director Cell Therapy External Manufacturing and Strategic Sourcing, Celgene, Sheng Lin-Gibson, Chief, NIST Biosystems and Biomaterials Division, Vadim Klyushnichenko, VP, Pharmaceutical Development and Quality, Cailbr at Scripps Research, William Shingler, Senior Director, Patient and Cell Management, Autolus Ltd